Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma

NCT05664243 is registered in ClinicalTrials.gov with In8bio Inc. as lead sponsor.

NCT NCT05664243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05664243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Lead sponsor
In8bio Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 8, 2023
Completion date
December 31, 2025
Enrollment
4 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma